TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8971427
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of captopril and ASA
Study: 8839527
Drug: Rectal temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal temperature measurement
Study: 26079743
Drug: Intensive antiplatelet
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) for one month
Study: 26079743
Drug: Guideline antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline antiplatelet therapy for one month
Study: 15044693
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ATRA and As(2)O(3)
Study: 16960167
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (17.6 mL/d, 1.8 g 20:5n-3, 3.0 g 22:6n-3, 5.9 g total n-3 fatty acids)
Study: 16960167
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (17.8 mL/d, 8.5 g 18:2n-6)
Study: 11722118
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin administration
Study: 9930635
Drug: Fluoxetine (FX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FX) 20 mg/day (n=67)
Study: 9930635
Drug: Amitriptyline (AM)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AM) daily dose: 115+/‐39.2mg (n=75)
Study: 9930635
Drug: Fluoxetine (FX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FX)
Study: 2921588
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 1.5 mg/70 kg
Study: 28240013
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy with biofeedback training
Study: 28240013
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy without biofeedback training (Control)
Study: 25409877
Drug: Light salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light salt (3 g daily for 4 weeks)
Study: 25409877
Drug: Regular salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular salt (3 g daily for 4 weeks)
Study: 23898483
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) 100 mg/kg orally, pre-treated 10 days before and 5 days after ADR treatment
Study: 23898483
Drug: Adriamycin (ADR)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADR) 20 mg/kg i.p.
Study: 20204604
Drug: Daily cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cholecalciferol 800 IU + calcium 1,000 mg for 3 years
Study: 16630670
Drug: Gemcitabine 10
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 10 mg/m2/min for 150 min on days 1 and 8 every 3 weeks by intravenous infusion at fixed dose rate (arm B)
Study: 29072016
Drug: Simple kegel
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple kegel exercise therapy
Study: 18165850
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (EGb761) 120 mg twice per day
Study: 12928941
Drug: Anakinra (Kineret®)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra (Kineret®) combined with anti-TNF agents
Study: 2113258
Drug: Kaolin-pectin solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaolin-pectin solution, diphenhydramine plus saline (KBS)
Study: 483371
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment in addition to a standard regime
Study: 483371
Drug: Standard regime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regime without steroids
Study: 28547735
Drug: Probable Medication-Overuse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probable Medication-Overuse Headache (pMOH)
Study: 19573383
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone solution (Iintropin AQ)
Study: 9040450
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 50 mg losartan and 10 mg enalapril
Study: 3189700
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids only (Control)
Study: 25530111
Drug: Revexepride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride (0.5 mg, three times daily)
Study: 22008690
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg intravenously) + 0.25% ropivacaine (2 mL per incision, 6 mL total)
Study: 22008690
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg intravenously) + 0.5% ropivacaine (2 mL per incision, 6 mL total)
Study: 22008690
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no analgesics administered)
Study: 19691368
Drug: Accumulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accumulation of MPAG(t) concentrations from 50 to 150 mg/L
Study: 19691368
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in plasma albumin concentration from 40 to 30 g/L
Study: 9635271
Drug: Epsilon aminocaproic
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon aminocaproic acid (EACA) - loading dose 15 mg/kg, continuous infusion 10 mg/kg per hour for 6 hours
Study: 1392155
Drug: VMMC protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group A: vindesine (2.5 mg/m2 day 1 and 8), mitoxantrone (12 mg/m2/day) every 4 weeks, mitomycin C (8 mg/m2) every 8 weeks
Study: 1392155
Drug: VMMC protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group B: vindesine (2.5 mg/m2), mitoxantrone (12 mg/m2) every 3 weeks on day 1, mitomycin C (8 mg/m2) every 6 weeks
Study: 3912735
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (control side)
Study: 26673433
Drug: ATX-101 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-101 (2 mg/cm)
Study: 19741509
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (ASA)
Study: 11228032
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management with medication, physiotherapy, or bracing
Study: 9158511
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg epirubicin in 50 mL normal saline 1-2 weeks after TURBT, repeated for 8 weeks and thereafter monthly for one year
Study: 9158511
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy after TURBT (control group)
Study: 8119091
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (Tissucol) applied as a spray (1 ml) at the end of the operation
Study: 3116982
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during nitrendipine treatment
Study: 3116982
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during placebo
Study: 352705
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active drug (placebo)
Study: 15100671
Drug: Desloratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (5 mg)
Study: 25351788
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g kg(‐1) ammonia chloride (ACD)
Study: 25351788
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g kg(‐1) calcium carbonate (PLA)
Study: 21337251
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment (combined sauna, cold water immersion, and jacuzzi) after the first match for post-PHV players
Study: 8160726
Drug: Evaluation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation and treatment of chest pain in patients with angiographically normal coronary arteries
Study: 2527534
Drug: Cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5 mg
Study: 23645534
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with temozolomide or irinotecan
Study: 16343498
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 mcg
Study: 18068887
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (self-etch adhesive)
Study: 17351746
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Afimoxifene gel
Study: 11258646
Drug: Moderate preliminary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate preliminary exercises (approximately 4 mmol/l lactate)
Study: 7748304
Drug: Serotonin uptake
Normalized name: Serotonin uptake inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin uptake inhibitors (SUI; e.g., citalopram, fluoxetine)
Study: 7748304
Drug: m‐CPP (5‐HT
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐CPP (5‐HT partial agonist)
Study: 7748304
Drug: Ondansetron (5‐HT3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (5‐HT3 antagonist, 0.5 mg/day)
Study: 7748304
Drug: Serotonin uptake
Normalized name: Serotonin uptake inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin uptake inhibitors (SUI) with brief psychosocial intervention
Study: 3433871
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg t.i.d. for 2 months
Study: 26967654
Drug: Recommendations for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations for trial preparation and conduct, including sensitisation meetings led by local leaders, involvement of Health Extension Workers, and use of local analogies for explaining randomisation.
Study: 16898002
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of S-1 (80 mg/m2 for 14 days) and docetaxel (DOC) starting at 40 mg/m2, increased to 50 mg/m2 at level 2.
Study: 10831272
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus immunotherapeutic agents (IFN‐α and/or IL‐2)
Study: 29939053
Drug: Attachment-Based Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-Based Family Therapy (ABFT)
Study: 16103515
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose at 2 mg x kg(‐1) x min(‐1)
Study: 2290270
Drug: Conventional IMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IMN tablets (Monisid, Bulgaria)
Study: 2290270
Drug: Long-acting IMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting IMN tablets (Olicard, FRG)
Study: 7338570
Drug: Bumetanide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (various doses in study 1 and 1 or 2 mg in study 2)
Study: 7338570
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 or 80 mg in study 2)
Study: 27438319
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of ticagrelor twice daily
Study: 27438319
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of ticagrelor twice daily
Study: 25196041
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of nicotine gum
Study: 16832816
Drug: Bortezomib at
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib at doses of 1.0 mg/m2, 1.3 mg/m2, or 1.5 mg/m2 on Days 1, 4, 8, and 11 of a 21-day treatment cycle for a maximum of 9 cycles
Study: 16832816
Drug: Bortezomib at
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib at 1.5 mg/m2
Study: 16832816
Drug: Bortezomib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (all doses)
Study: 2692653
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant chemotherapy (control group).
Study: 2692653
Drug: Cyclophosphamide 5
Normalized name: cyclophosphamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 5 mg/kg/day for six days, given 2-4 weeks after mastectomy (in a parallel study with 110 patients).
Study: 26491824
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g myo‐inositol, 10 mg monacolin K, 800 mg lipoic acid for 6 months
Study: 7519976
Drug: Cocaine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 0.4 mg/kg per dose, 10 or 11 doses at 30 min intervals (total dose range 233-408 mg)
Study: 3512031
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (heparin fragment)
Study: 15302008
Drug: Tezosentan 1
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 1 mg/h
Study: 15302008
Drug: Tezosentan 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 0.2 mg/h
Study: 11181472
Drug: Tezosentan 5
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 5 mg/h
Study: 11762740
Drug: Milk-based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based dietary supplements (powder reconstituted in fat-free milk)
Study: 11762740
Drug: Ready-to-drink milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-drink milk-based supplement
Study: 11762740
Drug: Low-lactose control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lactose control preparations
Study: 9420452
Drug: Low-dose micronutrient
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose micronutrient supplement containing trace minerals (zinc and selenium)
Study: 27433815
Drug: Cyclosporine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (2.5 mg/kg intravenous bolus at the onset of advanced cardiovascular life support)
Study: 19399562
Drug: Topical or
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical or intraductal fibrin glue
Study: 11560557
Drug: RTV :
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RTV : SQV 200 : 800 mg (E)
Study: 11560557
Drug: RTV :
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RTV : SQV 400 : 400 mg (B)
Study: 11560557
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens (E, F, G)
Study: 23517506
Drug: Intensive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive management (4 weekly review) for 48 weeks
Study: 23517506
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (12 weekly review) for 48 weeks
Study: 22051756
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg i.v.) in non-diabetics (n = 20)
Study: 16778364
Drug: lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole, 30 mg/day
Study: 3316518
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine added to metoclopramide and dexamethasone
Study: 31763732
Drug: Novel combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel combination powder (CP) - HEMOBLAST Bellows; Biom'up, France
Study: 30224318
Drug: Nintedanib 100
Normalized name: nintedanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 100 mg twice daily
Study: 26561294
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy at high-enrolling sites
Study: 26561294
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy at low-enrolling sites
Study: 26561294
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups at high-enrolling sites
Study: 26561294
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups at low-enrolling sites
Study: 21130380
Drug: Ecallantide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecallantide (30 mg subcutaneous)
Study: 2944997
Drug: Etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 400 mg
Study: 30912285
Drug: Ketone salts
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone salts (0.3 g β‐OHB per kg)
Study: 30912285
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester (0.482 g β‐OHB per kg)
Study: 29049251
Drug: Esmolol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 0.5 mg/kg
Study: 20329604
Drug: Bailing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bailing Capsule (BLC)
Study: 17877513
Drug: EBAL (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBAL (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., amoxicillin 1 g b.d. and levofloxacin 500 mg b.d.)
Study: 17877513
Drug: EBMT (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBMT (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., metronidazole 400 mg t.d.s. and tetracycline 500 mg q.d.s.)
Study: 2653325
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg daily for 2 months)
Study: 31359804
Drug: S-amlodipine 5
Normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine 5 mg for 10 days followed by S-amlodipine 5 mg plus bisoprolol 5 mg for 7 days
Study: 21667769
Drug: Explicit handwriting
Normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Explicit handwriting program (two weekly sessions of 45 min. over six weeks)
Study: 21667769
Drug: Regular handwriting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular handwriting program (one weekly session)
Study: 16641143
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (ergocalciferol 2.5 mg every 3 months, equivalent to a daily dose of 1,100 IU)
Study: 2142172
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cream
Study: 22065400
Drug: bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bosutinib 500 mg with food (therapeutic)
Study: 16020405
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg/day (increased to 10 mg as tolerated)
Study: 9857885
Drug: Lamifiban (GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamifiban (GP IIb/IIIa inhibitor)
Study: 23756346
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (750mg docosahexaenoic plus eicosapentaenoic acids, and 60mg gamma linolenic acid/school day) during Phase 1
Study: 23756346
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (after crossover in Phase 2)
Study: 18856250
Drug: Timed oral
Normalized name: C-Time Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed oral care (toothbrushing every 8 hours)
Study: 18856250
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral care (control group)
Study: 16243588
Drug: Elemene injections
Normalized name: (-)-beta-Elemene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemene injections
Study: 3900905
Drug: Rifampin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin, 10 mg/kg, twice a day for four days
Study: 3900905
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for four days
Study: 3900905
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug regimens (including placebo)
Study: 3900905
Drug: Anticapsular antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticapsular antibody concentration measurement
Study: 19921230
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (8 IU)
Study: 29750971
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (1 IU)
Study: 24839144
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (LF) 200 mg/d
Study: 20590588
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (0.2 mg x kg(‐1)) alone